These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27755520)

  • 1. [The kynurenic acid hypothesis - a new look at etiopathogenesis and treatment of schizophrenia].
    Flis M; Szymona K; Morylowska-Topolska J; Urbańska A; Krukow P; Kandefer-Szerszeń M; Zdzisińska B; Urbańska EM; Karakuła-Juchnowicz H
    Pol Merkur Lekarski; 2016 Sep; 41(243):160-164. PubMed ID: 27755520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of aryl hydrocarbon receptors increases endogenous kynurenic acid levels and protects mouse brain against excitotoxic insult and oxidative stress.
    García-Lara L; Pérez-Severiano F; González-Esquivel D; Elizondo G; Segovia J
    J Neurosci Res; 2015 Sep; 93(9):1423-33. PubMed ID: 26013807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does kynurenic acid act on nicotinic receptors? An assessment of the evidence.
    Stone TW
    J Neurochem; 2020 Mar; 152(6):627-649. PubMed ID: 31693759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New prospects for antipsychotic treatment - the role of the kynurenine pathway].
    Karakuła-Juchnowicz H; Flis M; Szymona K; Kuczyńska M; Stelmach E; Kowal-Popczak A
    Psychiatr Pol; 2014; 48(6):1167-77. PubMed ID: 25717486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex.
    Wu HQ; Pereira EF; Bruno JP; Pellicciari R; Albuquerque EX; Schwarcz R
    J Mol Neurosci; 2010 Jan; 40(1-2):204-10. PubMed ID: 19690987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia.
    Olsson SK; Andersson AS; Linderholm KR; Holtze M; Nilsson-Todd LK; Schwieler L; Olsson E; Larsson K; Engberg G; Erhardt S
    Int J Neuropsychopharmacol; 2009 May; 12(4):501-12. PubMed ID: 18796185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients.
    Myint AM; Schwarz MJ; Verkerk R; Mueller HH; Zach J; Scharpé S; Steinbusch HW; Leonard BE; Kim YK
    Brain Behav Immun; 2011 Nov; 25(8):1576-81. PubMed ID: 21620952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain.
    Ceresoli-Borroni G; Rassoulpour A; Wu HQ; Guidetti P; Schwarcz R
    J Neural Transm (Vienna); 2006 Oct; 113(10):1355-65. PubMed ID: 16465454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased Plasma Levels of Kynurenine and Kynurenic Acid in Previously Treated and First-Episode Antipsychotic-Naive Schizophrenia Patients.
    Marković M; Petronijević N; Stašević M; Stašević Karličić I; Velimirović M; Stojković T; Ristić S; Stojković M; Milić N; Nikolić T
    Cells; 2023 Dec; 12(24):. PubMed ID: 38132134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The kynurenine pathway in schizophrenia and bipolar disorder.
    Erhardt S; Schwieler L; Imbeault S; Engberg G
    Neuropharmacology; 2017 Jan; 112(Pt B):297-306. PubMed ID: 27245499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlations of Kynurenic Acid, 3-Hydroxykynurenine, sIL-2R, IFN-α, and IL-4 with Clinical Symptoms During Acute Relapse of Schizophrenia.
    Szymona K; Zdzisińska B; Karakuła-Juchnowicz H; Kocki T; Kandefer-Szerszeń M; Flis M; Rosa W; Urbańska EM
    Neurotox Res; 2017 Jul; 32(1):17-26. PubMed ID: 28275903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects.
    Müller N; Myint AM; Schwarz MJ
    Curr Pharm Des; 2011; 17(2):130-6. PubMed ID: 21361867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.
    Linderholm KR; Skogh E; Olsson SK; Dahl ML; Holtze M; Engberg G; Samuelsson M; Erhardt S
    Schizophr Bull; 2012 May; 38(3):426-32. PubMed ID: 20729465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release.
    Zmarowski A; Wu HQ; Brooks JM; Potter MC; Pellicciari R; Schwarcz R; Bruno JP
    Eur J Neurosci; 2009 Feb; 29(3):529-38. PubMed ID: 19187269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges.
    Albuquerque EX; Schwarcz R
    Biochem Pharmacol; 2013 Apr; 85(8):1027-32. PubMed ID: 23270993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast.
    Cosi C; Mannaioni G; Cozzi A; Carlà V; Sili M; Cavone L; Maratea D; Moroni F
    Neuropharmacology; 2011 Jun; 60(7-8):1227-31. PubMed ID: 21110987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Tryptophan-Derived AhR Ligands, Kynurenine, Kynurenic Acid and FICZ, on Proliferation, Cell Cycle Regulation and Cell Death of Melanoma Cells-In Vitro Studies.
    Walczak K; Langner E; Makuch-Kocka A; Szelest M; Szalast K; Marciniak S; Plech T
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.
    Erhardt S; Olsson SK; Engberg G
    CNS Drugs; 2009; 23(2):91-101. PubMed ID: 19173370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine.
    Alexander KS; Wu HQ; Schwarcz R; Bruno JP
    Psychopharmacology (Berl); 2012 Apr; 220(3):627-37. PubMed ID: 22038535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: implications for schizophrenia.
    Pershing ML; Bortz DM; Pocivavsek A; Fredericks PJ; Jørgensen CV; Vunck SA; Leuner B; Schwarcz R; Bruno JP
    Neuropharmacology; 2015 Mar; 90():33-41. PubMed ID: 25446576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.